Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share

Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.08), versus (GBP0.06) reported last year.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal
• DigitalOcean projects record Q2 2026 results with RPO above $800M